A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Clinical trial NCT05625399 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05625399
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-06
- Primary completion
- 2025-08-04
- Enrollment
- 579
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.